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Abstract
Introduction: We characterized false negative prostate magnetic 
resonance imaging (MRI) reporting by using histology derived from 
MRI-transrectal ultrasound (TRUS)-guided transperineal (MTTP) 
fusion biopsies. 
Methods: In total, 148 consecutive patients were retrospectively 
reviewed. Men underwent multiparametric MRI (mpMRI), reported 
by a consultant/attending radiologist in line with European 
Society of Urogenital Radiology (ESUR) standards. MTTP biop-
sy of the lesions was performed according to the Ginsburg 
recommendations. Cases with an MRI-histology mismatch were 
identified and underwent a second read by an experienced radi-
ologist. A third review was performed with direct histology 
comparison to determine a true miss from an MRI-occult 
cancer. Statistical analysis was performed with McNemar’s test.
Results: False negative lesions were identified in 29 MRI exami-
nations (19.6%), with a total of 46 lesions. Most false negative 
lesions (21/46) were located in the anterior sectors of the prostate. 
The second read led to a significant decrease of false-negative 
lesions with 7/29 further studies identified as positive on a patient-
by-patient basis (24.1% of studies, p = 0.016) and 11/46 lesions 
(23.9%; p = 0.001). Of these, 30 lesions following the first read and 
23 lesions after the second read were considered significant cancer 
according to the University College London criteria. However, on 
direct comparison with histology, most lesions were MRI occult. 
Conclusion: We demonstrate that MRI can fail to detect clinically 
relevant lesions. Improved results were achieved with a second 
read but despite this, a number of lesions remain MRI-occult. 
Further advances in imaging are required to reduce false negative 
results.
Introduction 
Current methods for risk stratification of prostate cancer, 
including serum prostate-specific antigen (PSA) and tran-
srectal ultrasound (TRUS)-guided biopsies, are limited by 
sampling error and low sensitivity and specificity.1-3 TRUS-
biopsy can lead to inaccurate grading of 32% to 42% of 
cancers,4-6 and may fail to detect 30% to 50% of cancers, 
particularly tumours in the anterior portion of the prostate.7-12 
The improvement in multiparametric magnetic resonance 
imaging (mpMRI) in detecting prostate cancer has led to its 
recommendation in high-risk patients following a negative 
TRUS biopsy.13 MRI can then be used to guide subsequent 
biopsy either cognitively, in-bore (direct MRI-targeting), or 
by using MRI-TRUS fusion techniques.14-17 The latter com-
bines anatomical MRI localization with the real-time guid-
ance of ultrasound. Repeat biopsy is often undertaken by the 
transperineal (TP) route as this offers potential advantages 
over a transrectal route, including better sampling of the 
anterior and apical regions of the prostate, reduced false 
negative results, and a sterile approach.18
mpMRI has the potential to accurately exclude prostate 
cancer and reduce biopsy burden.19,20 To achieve this, it 
must have a high negative predictive value (NPV) on a 
patient-by-patient basis and maintain sufficient accuracy 
on a lesion-by-lesion basis to correctly stratify patients.21
However, current reported figures for the NPV for mpMRI 
range from 60% to 100%.19,22,23 This variation depends on 
the studied population, the MRI protocol, the definitions 
of significant cancer, and the method of analysis. Another 
variable is the experience of the radiologist reporting the 
MRI.24,25 The reliability of a negative MRI is a key clinical 
metric – if the MRI is reported as positive for cancer, the 
patient will undergo a biopsy irrespective of whether this is 
a true positive or a false positive; however, a negative MRI 
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may mean a patient is discharged without need for a biopsy. 
It is therefore important for an MRI to accurately exclude 
tumour, and a low false negative (FN) rate is a key deter-
minate of whether this approach is clinically feasible. We 
therefore aimed to assess and characterize the false-negative 
mpMRI at our centre, using histology from MRI-TRUS fusion 
transperineal biopsy sets as a validation tool. 
Methods 
This retrospective review of outcomes was granted local 
ethical approval, with the need for written informed con-
sent waived. Consecutive patients undergoing MRI-TRUS 
fusion transperineal biopsy from June 2011 to May 2013 
were included. Cases where MRI was performed at an out-
side institution or where the MRI was greater than 8 weeks 
pre-biopsy, were excluded. 
In total, 148 patients were included for analysis, of which 
128 patients (86.5%) had a least 1 prior negative TRUS 
biopsy. Indications for biopsy included the following� per-
sistently raised PSA, abnormal digital rectal examination, or 
suspicious histology from previous TRUS-biopsy (high-grade 
prostatic intraepithelial neoplasia [HG-PIN] or atypical small 
acinar proliferation). 
MRI    
Patients underwent prostate MRI on a 3T HDx or 1.5 T 
MR450 scanner (GE-Healthcare, Waukesha, WI) without 
an endorectal coil. T2-weighted Fast Spin-Echo images of 
the prostate were acquired in the axial, sagittal and coronal 
planes (TE/TR = 85/3700–5000 ms; field-of-view [FOV] was 
24 × 24 cm; matrix 256 × 256; slice thickness/gap 3/1 mm). 
Diffusion-weighted imaging (DWI) was TE/TR = 60/3000–
3400 ms; matrix 256 × 256; slice thickness/gap 4/0 mm; 
FOV was 24 × 24 cm 1.5 T, 28 × 28 cm 3T; parallel imaging 
factor 2; signal averages were 3 for 1.5T, 8 for 3T; b-values 
were 150, 750, 1400 s/mm2, with calculated automated 
apparent diffusion coefficient (ADC) maps.
Exams were reported clinically by a consultant/attending 
radiologist with at least 3 years prostate MRI reporting expe-
rience. The prostate was divided into 27 sectors, with targets 
defined by location and level of suspicion, as previously 
described.26 T2-weighted and DWI sequences were evalu-
ated using the Prostate Imaging Reporting and Data System 
(PI-RADS) structured scoring descriptors, developed by the 
ESUR.27 Based on these descriptors, an overall suspicion for 
each MR lesion was recorded using a Likert scale� 1� cancer 
highly unlikely; 2� cancer unlikely; 3� indeterminate for can-
cer; 4� cancer likely; and 5� cancer highly likely. A positive 
MRI was defined as a score of ≥3. 
Biopsy protocol 
Patients had MTTP biopsies, according to Ginsburg group 
protocols, performed by 1 of the 3 experienced consul-
tant/attending urologists not blinded to the MRI reports.28 
Patients had targeted biopsies of MRI detected lesion or 
lesions (Likert score ≥3), followed by 24 to 36 systematic 
sectoral biopsies.27
Histopathology and correlation with MRI 
Biopsies were reported by a consultant/attending uropathol-
ogist who was unaware of the MRI findings, and reported 
according to published guidelines.28 Lesion location was 
described according to the Ginsburg sector map.28 Each 
core was measured and the percentage of cancer estimat-
ed. Significant cancer was defined by University College 
London (UCL) criteria29� green (Gleason ≤3+3, maximum 
cancer core length [mCCL] ≤3 mm), amber (Gleason 3+4, 
≤5 mm, or Gleason 3+3, mCCL 4–10 mm) and red (Gleason 
≥4+3 or Gleason 3+4, mCCL ≥6 mm or Gleason 3+3, mCCL 
≥11 mm).
Study design 
Histology from all biopsies in 148 patients were reviewed and 
compared to initial MRI reports. Location of lesions reported 
by MRI sector map was converted into the Ginsburg sector 
map nomenclature (Table 1). All cases with one or more MRI-
histology mismatches were identified and selected for further 
characterization, except when mismatch occurred between 
Table 1. Conversion table of the anatomic prostatic MRI 
zones (PI-RADS mapping system)26 and histologic sectors 
(Ginsburg mapping system)27 
Specimen 
name
Description MRI mapping equivalent
1M Right anterior medial 13as/14as/15as (1a/3a)
1L Right anterior lateral 13as/14as/15as
2M Right mid medial (apex) 1a/1p/3a/3p/5a/5p
2B Right mid medial base 1a/3a (1p)
2L Right mid lateral 2a/4a/6a
3M Right posterior medial 1p/3p/5p
3L Right posterior lateral 2p/4p/6p
4M Left posterior medial 7p/9p/11p
4L Left posterior lateral 8p/10p/12p
5M Left mid medial (apex) 7a/7p/9a/9p/11a/11p
5B Left mid medial base 7a/9a (7p)
5L Left mid lateral 8a/10a/12a
6M Left anterior medial 13as/14as/15as (7a/9a)
6L Left anterior lateral 13as/14as/15as
Due to overlap between the two systems, some zones were included in more than one of 
the histological sectors as shown in parenthesis. MRI: magnetic resonance imaging; PI-
RADS: Prostate Imaging Reporting and Data System.
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adjacent prostatic regions. In total, 29 patients were identified 
with false-negative lesions (i.e., at least 1 lesion on histology 
not reported on initial MRI). These examinations were then 
re-read by a radiologist with 5-years experience in prostate 
MRI reporting (FAG), blinded to the clinical details and biopsy 
results. This second read was performed retrospectively, after 
TP biopsy, and therefore did not affect clinical outcomes. At a 
subsequent session, the 29 studies were reviewed with histolo-
gy results available (EMS, FAG), with each false-negative lesion 
assigned as follows� 1� true miss with lesion retrospectively 
identified on MRI in biopsy-positive region (false-negative 
reporting); 2� non-specific MRI features in histology-positive 
region; 3� no lesion identified (false-negative MRI); 4� mis-
called zone (lesion identified, but incorrect zone reported); 
and 5� image artifact significantly affecting interpretation.
Statistics 
Data analysis was performed with SPSS (v21, IBM-SPSS, 
Chicago, IL). Statistical significance was determined using 
McNemar’s test to assess the null hypothesis of marginal 
homogeneity, which states that the probability of each char-
acterization by the 2 raters is the same. Since the numbers 
in discordant cells were small, exact binominal probability 
p values were used. A p value <0.05 was considered sta-
tistically significant. The effect of sector location on cancer 
significance was estimated as an odds ratios (OR) using 
logistic regression.
Results 
Of the 148 patients, 73 had a least 1 biopsy core which 
was positive for cancer (49.3%) (Table 2). A total of 232 
lesions from the 148 patients were prospectively reported 
as “MRI positive” (mean 1.57 lesions/patient; median 2), 
and proceeded to a targeted biopsy, of which 174 (75%) 
were positive for cancer. A total of 220 positive biopsies 
were identified histologically, with 102/220 as UCL category 
green and 118/200 as amber or red. Of the 220 positive 
biopsies, 46 (20.9%) were in areas determined falsely nega-
tive on MRI. 
Of the 148 pateints, 29 (19.6%) had at least 1 FN lesion 
on MRI, with 28/29 patients having ≥1 lesion reported else-
where in the gland and histologically confirmed as cancer; 
for one, no lesion was described. For these 29 patients, 23 
(79.3%) were scanned a 3T and 6 (20.7%) at 1.5T. The 
probability of classifying prostatic sectors into positive 
(lesion present) or negative (no lesion) by the 2 readers was 
significantly different (p = 0.001). The second MRI read 
led to a significant decrease of false negative lesions on a 
patient-by-patient basis (reduced 24.1%; in 7/29 patients; 
p = 0.016) and a lesion-by-lesion basis (23.9%, 11/46 
lesions, p = 0.001) (Table 3). The second read improved 
sensitivity for lesion detection from 79% to 84%. Of the 
46 lesions, 30 were in 18 of the 29 patients missed at first 
read; they represented UCL-defined significant cancer and 
the number of lesions reduced to 23 lesions (p = 0.016) in 
12 patients (p = 0.031) at second read (Table 3).  
At the second read, of the 35 FN lesions, 15 were MRI-
invisible even when comparing directly to histology. Non-
specific focal features were found in 10/35 lesions after 
the second read, with 7/10 being significant cancers. True 
misses (Fig. 1) still accounted for 7/35 lesions after the sec-
ond reading.  
Table 2. Table of the demographics of the 29 men with FN 
lesions on mpMRI compared to all patients
Total values  
(148 patients)
MRI FN values (29 
patients)
Age, years; median (range) 65 (48-79) 67 (52-77)
Initial PSA, ng/mL; median 
(range)
9.55 (0.7-150) 11.66 (1.3–36.5)
Biopsy
No. cores per patient; mean 
(range)
30 (19-56) 28 (19-39)
Total no. cores (mean) 4393 (29.7) 818 (28.2)
Gleason grade (%)
n = 73 biopsy 
positive (in 148 
patients)
n = 46 lesions (in 
29 patients)
3 + 3 38 (52.1%) 23 (50%)
3 + 4 16 (21.9%) 9 (19.6%)
4 + 3 4 (5.5%) 6 (13%)
≥4 + 4 15 (20.5%) 8 (17.4%)
mpMRI: multiparametric magnetic resonance imaging; FN: false negative; PSA: prostate-
specific antigen.
Table 3. Retrospective MRI classification of the total 
false negative MRI lesions and of those that represented 





True miss (FN report) 10 7
Non-specific features 12 10
No feature of a focal lesion (FN MRI) 19 15
Miscalled zone 3 1
Difficult interpretation 2 2
Total (lesions): 46 35*
MRI classification
Significant cancers (amber 
or red on UCL criteria)
MRI report Second read
True miss 7 4
Non-specific features 8 7
No features of a focal lesion 11 10
Miscalled zone 2 0
Difficult interpretation 2 2
Total (lesions) 30 23*
*p ≤ 0.05. FN: false negative; MRI: magnetic resonance imaging.
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The greatest proportion of false negative lesions (21/46) 
were in the anterior prostate sectors (Fig. 2). Although a 
higher proportion of significant cancers were also located 
anteriorly (12/30), and the sector location had no effect on 
cancer significance (OR 1.056, p = 0.544).
Of the 29 patients with FN lesions, 3 underwent pros-
tatectomy, 10 radiotherapy with hormonal therapy, 2 
brachytherapy, 2 hormonal therapy, 2 focal-therapy, and 10 
enrolled to active surveillance. Analysis of the prostatectomy 
patients showed good agreement between biopsy and final 
pathology (Fig. 3), except in 1 patient with over-grading by 
TP biopsy (Gleason 4+5; final pathology 4+3 with tertiary 5).
Discussion 
mpMRI of the prostate is becoming established in the routine 
workup of patients with suspected prostate cancer and is 
increasingly used for lesion detection in men with negative 
TRUS biopsies and with persistent suspicion of cancer.13,30
MRI-guidance in this setting increases the detection of clini-
cally significant cancer compared to standard approach-
es.15,31,32 MRI may in the future be performed prior to biopsy 
as a strategy to triage men with raised PSA and to select the 
best approach for biopsy.3,20 This study has shown that initial 
mpMRI missed at least 1 focus of cancer in 29/148 (19.6%) 
of patients, corresponding to 46 lesions, 65% of which were 
considered significant cancers.
Previous studies have demonstrated that approximately 
one-fifth of men with histologically-proven cancer on stan-
dard biopsy had a negative MRI.15,16,33 It is noteworthy that 
these studies were performed in biopsy-naïve men, whereas 
our cohort included men with a previous negative TRUS 
biopsy. We are therefore likely to have excluded larger, 
more posteriorly located tumours, for which MRI is known 
to have a higher sensitivity. The second reading, despite its 
retrospective nature, was shown to be beneficial in reduc-
ing both the number of true misses and the overall number 
of FN examinations. This highlights the potential advantage 
for double-reading of selected high-risk cases by an experi-
enced radiologist, or possibly even routine double-reading, 
which is standard practice in some areas of radiology, such 
as screening mammography. 
Most FN MRI lesions were not identified on MRI even after 
retrospective review. One such case had no MRI-detectable 
lesions despite the presence of significant cancer in 3 differ-
ent regions. This may reflect the volume of diseased tissue 
required per MRI voxel for lesions to be detected, sparsity 
of tumour growth, or the intrinsic limitations of MRI.34-36
Indeed, MRI is known to be poor at detecting low-grade, 
low-volume cancer, lacking sensitivity even in cases where 
the predominant Gleason pattern is 4, but the cancer volume 
is <0.2 cm3.36-38 These factors reflect the need for further 
advances in imaging to detect such lesions. We found that 
anterior lesions were more likely to be missed than lesions 
elsewhere within the prostate, which reflects the known 
difficulty in identifying cancer within the heterogeneous 
transition zone (TZ) and fibromuscular stroma.39,40
Our study has limitations, including its retrospective 
nature. Despite the fact that transperineal template biopsies 
perform well in detecting significant disease, any biopsy 
technique is prone to sampling error.29,41 As this study was 
Fig. 1. Demonstration of a true miss. A 69-year-old man with a prostate-specific 
antigen of 18 ng/mL. Bilateral anterior high probability targets (*) were called 
on axial T2 images (A) and apparent diffusion coefficient (ADC) maps (C). 
Histology confirmed a Gleason 4+3 lesion in 25% of cores from the anterior 
zones (1 and 6). A magnified axial T2 image (B) and ADC map (D) is shown 
corresponding to each inset box. There was an additional Gleason 3+4 lesion 
in the left posterior lateral zone (4L) involving 5% of the core. The latter was 
missed even after two separate reads, but on direct comparison with the 
histology, the lesion was identified (arrows in B and D).
Fig. 2. Distribution of the false negative lesions. The relative size of circles 
reflects the percentage of false negatives in each prostate sector in the axial 
plane, according to the Ginsburg mapping system. This system divides the 
prostate into 3 antero-posterior with no differentiation between apex, mid and 
base (except for 2B and 5B which are not shown), unlike the PI-RADS system, 
which is frequently used for prostate magnetic resonance imaging reporting. 
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performed as part of routine clinical practice, MRI was 
undertaken at both 1.5T and 3T. The study was not designed 
to assess whether field strength affects the false negative rate 
of MRI and further research is required to determine whether 
3T imaging of the prostate yields a lower false negative rate 
than 1.5T. Additionally, dynamic contrast-enhanced (DCE) 
MRI was not performed as it was not standard-of-care in 
our institution at the time of this study, although there is 
some evidence that it can help improve sensitivity over DWI 
alone.27,42,43 However, most lesions were in the TZ and the 
recently updated PI-RADS guidelines suggest DCE-MRI has 
no role to play in assessment of the TZ in the presence of 
adequate DWI and T2-weighted imaging.44 There is differ-
ing nomenclature between the radiological sector-maps for 
reporting MRI-tumour location and the Ginsburg uropathol-
ogy system used for obtaining and reporting biopsies; this 
may account for some analysis errors, as correlation of the 
MRI location to biopsy sectors becomes more challenging. 
The radiology map employed here incorporated 2 regions in 
the anterio-posterior plane, compared to 3 in the Ginsburg 
system (Fig.2); interestingly, a more updated radiological 
map now includes 3 anterio-posterior sectors medially.45
Conversely, the Ginsburg system does not differentiate the 
apex, mid and base of the prostate; although this can be 
overcome by the inking of biopsy cores, this will incur addi-
tional time and cost.26,28
It is important to note that in clinical practice factors 
other than MRI are used to help determine whether a patient 
requires further investigation. This study has been designed 
to assess the FN rate for MRI alone; combining imaging 
with other investigations to reduce FNs are required in the 
future. We have demonstrated that a high proportion of FN 
lesions can be reduced by a second read, which is important 
information for the clinical community and underlines the 
need for further studies to address how multiple tests can 
be used together to reduce the need for biopsy. 
Conclusion 
This study shows that MRI reporting can miss clinically rel-
evant lesions. Improved results were achieved with a sec-
ond read by an experienced radiologist. However, despite 
careful correlation to histology results, a number of lesions 
remained occult on MRI, demonstrating the limitations of 
existing sequences for the detection of some lesions and 
the need for further improvements in imaging in the future.
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